X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
KSI-301 (tarcocimab tedromer) is designed to maintain potent and effective drug levels in ocular tissues for longer than existing anti-VEGF therapies, which is investigated for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
Lead Product(s): Tarcocimab Tedromer
Therapeutic Area: Ophthalmology Product Name: KSI-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
KSI-301 (tarcocimab tedromer) is designed to maintain potent and effective drug levels in ocular tissues for longer than existing anti-VEGF therapies, which is investigated for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
Lead Product(s): Tarcocimab Tedromer
Therapeutic Area: Ophthalmology Product Name: KSI-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
KSI-501 is a bispecific ABC that is designed to inhibit two mechanisms implicated in vascular endothelial growth factor ("VEGF") and interleukin-6 (IL-6), a pro-inflammatory cytokine and growth factor implicated in the pathophysiology of multiple retinal diseases.
Lead Product(s): KSI-501
Therapeutic Area: Ophthalmology Product Name: KSI-501
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
KSI-301 (tarcocimab tedromer) is an investigational anti-VEGF therapy built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform and is designed to maintain potent and effective drug levels in ocular tissues for longer than existing available agents.
Lead Product(s): Tarcocimab Tedromer
Therapeutic Area: Ophthalmology Product Name: KSI-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
Details:
Tarcocimab tedromer (KSI-301) dosed every two months met the primary endpoint of non-inferior visual acuity gains compared to aflibercept dosed every month, in patients with macular edema due to retinal vein occlusion.
Lead Product(s): Tarcocimab Tedromer
Therapeutic Area: Ophthalmology Product Name: KSI-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
KSI-301 is an investigational anti-VEGF therapy built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform and is designed to maintain potent and effective drug levels in ocular tissues for longer than existing available agents.
Lead Product(s): KSI-301
Therapeutic Area: Ophthalmology Product Name: KSI-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
KSI-301 is an investigational anti-VEGF therapy built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform and is designed to maintain potent and effective drug levels in ocular tissues for longer than existing available agents.
Lead Product(s): KSI-301
Therapeutic Area: Ophthalmology Product Name: KSI-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2022
Details:
Results show that KSI-30, anti-VEGF therapy demonstrated strong durability and was safe and well-tolerated, did not meet primary efficacy endpoint showing non-inferior visual acuity gains for subjects dosed on extended regimens compared to aflibercept given every eight weeks.
Lead Product(s): KSI-301
Therapeutic Area: Ophthalmology Product Name: KSI-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2022
Details:
KSI-301, is an investigational anti-VEGF therapy built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform and is designed to maintain potent and effective drug levels in ocular tissues for longer than existing available agents.
Lead Product(s): KSI-301
Therapeutic Area: Ophthalmology Product Name: KSI-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2022
Details:
Over 550 patients with macular edema secondary to retinal vein occlusion enrolled worldwide for Phase 3 BEACON study which is designed to evaluate the durability, efficacy, and safety of KSI-301, an investigational anti-VEGF therapy.
Lead Product(s): KSI-301
Therapeutic Area: Ophthalmology Product Name: KSI-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
